Articles tagged with Vaccine Target
The University of Montana has received a $3.3 million contract from the National Institutes of Health to develop an opioid addiction vaccine. The vaccine targets fentanyl and prevents it from crossing the blood-brain barrier, offering a promising safe and cost-effective strategy to treat opioid use disorders.
Scientists have developed a new single vaccination approach that simultaneously protects against both influenza and pneumococcal infections, overcoming the limitations of current vaccines. The approach combines vaccines targeting different components of the virus and bacteria, inducing enhanced cross-protective immunity.
Researchers have developed techniques to personalize anticancer vaccines based on individual patient genomic information, targeting unique tumor mutations. Early results show promise in inducing potent immune responses.
A new DNA vaccine targeting the human MAGE-A family of proteins has shown promise in a pre-clinical model of melanoma, inducing a robust immune response and antitumor activity. The vaccine simultaneously targets multiple tumor antigens, overcoming a difficult issue in cancer immunotherapy.
Researchers have successfully deployed a Zika virus vaccine to target and kill human glioblastoma brain cancer stem cells in mice, offering a potential new treatment option. The vaccine demonstrated effectiveness in delaying tumor development and prolonging survival time in mouse models.
Researchers have developed vaccines against heroin and prescription opioids that target the brain's opioid receptors, preventing addiction-relevant behaviors. The vaccines appear safe and effective in blocking opioid distribution to the brain, potentially helping prevent fatal overdoses.
A team of researchers has identified a 'genetic fingerprint' associated with the most deadly strains of malaria parasites. They found that only 20-30 var gene pieces were being expressed at a higher rate in patients with severe malaria, providing promise for new targets for vaccine design.
A new Yale study reveals that gut bacteria can travel to other organs and trigger an autoimmune response. Researchers found that suppressing the growth of Enterococcus gallinarum with an antibiotic or vaccine can suppress autoimmunity in mice with chronic autoimmune conditions.
A study modeling cholera epidemics suggests that targeting vaccine and other interventions to areas around existing cholera cases is an effective way to control outbreaks. The results indicate that oral cholera vaccine is the most effective intervention, with a radius of 70-100 meters being optimal for administration.
A study suggests that targeting the 'stalk' of the hemagglutinin protein, which remains relatively constant across flu strains, could provide broad protection against seasonal and pandemic strains. However, the results also show that the stalk can mutate in response to immune pressure.
Scientists have discovered five new targets that can help create an effective malaria vaccine by reducing the parasite's ability to invade red blood cells. The study suggests combining these multiple factors could lead to a more effective vaccine.
Research published in Genome Medicine found that a broad cancer vaccine targeting multiple neo-antigens could only be effective for less than 0.3% of the population, based on analysis of over 60,000 unique tumors.
A new cancer treatment combines four therapies to activate both branches of the immune system, leading to complete disappearance of large tumors in mice. The approach allows the immune system to remember the target and destroy new cancer cells that appear after treatment.
Researchers found that the key viral protein used in candidate HCV vaccines is surprisingly flexible, elicit a wide variety of antibodies that cannot block viral infection. This flexibility may be why current vaccines have been ineffective in preventing HCV infection.
Researchers developed a new type of nanoparticle vaccine that effectively vaccinated mice against one dengue virus serotype. The vaccine targets only one strain, but its development could pave the way for vaccines against all four serotypes, potentially offering better protection against life-threatening disease.
Researchers aim to develop a multi-layered defense strategy targeting mucosal barriers, blood, and tissues. The goal is to induce host defenses against HIV simultaneously at multiple levels.
Researchers will study immune responses of 200 volunteers with diagnosed or symptomatic Zika, analyzing blood specimens to understand body's response. Understanding natural history and immune system could identify targets for treatments and vaccines.
Researchers at the University of Oklahoma Health Sciences Center are working to develop a vaccine for the Zika virus, using their experience with West Nile virus. They aim to identify specific parts of the virus that can be targeted by the immune system, and have received $230,000 in NIH funding for their research.
Researchers identified Zika virus protein NS5 as a promising target for vaccines, inhibiting human interferon responses by blocking STAT2 protein. The study found altered or removed NS5 could trigger the human immune system to attack the virus, making it a potential vaccine candidate.
Researchers discovered a new vulnerable site on HIV called the fusion peptide, which has a simpler structure than other sites studied. A broadly neutralizing antibody targeting this site could help prevent HIV infection by binding to key cell-surface molecules.
Scientists have designed a new vaccine that increases anti-nicotine antibodies, delaying nicotine's effects in mice. This approach shows promise for reducing cravings and aiding smokers in quitting
Researchers have identified specific immune cells that could be targeted by a new MRSA vaccine. These 'T-helper type 1' cells play a critical role in the immune response and are elevated in patients following MRSA infection. A model vaccine targeting these cells has shown improved infection outcomes.
Researchers at Osaka University have discovered a new role for p62 in the immune response to Toxoplasma gondii, paving the way for the development of an inactivated vaccine. The study found that p62 plays a crucial role in activating killer T cells in infected cells stimulated by interferon-γ.
The NIH-funded study found that the RTS,S vaccine was most effective against malaria in children with the same protein variant, while a mismatch corresponded to lesser protection. The research used advanced genomic sequencing technology to investigate genetic variations in the CS protein, which may limit or restrict vaccine protection.
The Alliance for Aging Research released a white paper highlighting the factors driving low vaccination rates among seniors and offering recommendations for improvement. Vaccination rates are lower than target levels set by Healthy People 2020, resulting in significant health issues and deaths among older adults.
The human papillomavirus (HPV) vaccine is currently required in only two US states, with vaccination coverage substantially below the Healthy People 2020 target. A recent study found that HPV vaccination rates are lower than those for other adolescent vaccines, such as hepatitis B and meningococcal conjugate vaccines.
Researchers discovered new vaccine targets that could help combat malaria by identifying previously untested antigens and gaining insights into antigen combination. A group of infected children was followed over six months to identify combinations of antibodies providing up to 100% protection against clinical episodes.
Scientists at the Scripps Research Institute have discovered that a single site on the surface protein of HIV can be targeted by an AIDS vaccine, potentially neutralizing nearly all strains of the virus. The study suggests that this approach could lead to a highly effective vaccine that targets a specific site on the Env protein.
Research reveals young women most at risk of cervical cancer are least likely to be offered and complete the HPV jab. The survey found that these women need targeted efforts to improve vaccination uptake, which was below 80% required for significant impact on cervical cancer rates.
A new Phase III clinical trial at Cedars-Sinai Samuel Oschin Comprehensive Cancer Institute aims to provide kidney cancer patients with long-term control of their disease. The vaccine-based approach uses a patient's own immune system to fight the disease, potentially improving survival outcomes and quality of life.
Aaron Esser-Kahn, Sunil Gandhi, and Ali Mortazavi will each receive $2.3 million to fund their projects, focusing on vaccine development and neural plasticity. Their work aims to improve human health by transforming scientific fields.
A recent study by the Norwegian Institute of Public Health found no increased risk of fetal death associated with pandemic vaccination. The study analyzed data from pregnant women who received COVID-19 vaccines and compared them to those who did not receive vaccines.
Researchers have found that targeting human endogenous retroviruses (HERVs) can effectively eliminate HIV-infected cells using immune responses. This discovery could lead to the development of novel HIV vaccines by leveraging HERV-targeted T-cells.
The incidence of invasive cervical cancer has declined dramatically over the past several decades, thanks to increased use of Pap smears and prevention programs. However, disparities persist, particularly among underserved racial and ethnic minorities, rural areas, and low-income women.
Researchers at Newcastle University have identified a new type of white blood cell that activates a killing immune response to external sources, providing a potential target for vaccines. The discovery could lead to the development of targeted immunotherapies against cancer and infections such as Hepatitis B.
A study published in Pediatrics found that HPV vaccination significantly reduced infection rates among both vaccinated and unvaccinated young women. The vaccine's effectiveness was particularly notable among sexually experienced participants.
Scientists have pinpointed the region on dengue virus that humans target with their immune system, challenging current vaccine research. The discovery reveals human antibodies bind to a complex structure on assembled dengue viruses, not small fragments as previously thought.
The malaria parasite changes into a banana shape before sexual reproduction to evade the human immune system and survive in the circulation. This finding provides new targets for vaccine or drug development.
A new vaccine has been developed to protect against group B meningococcal disease, a major cause of meningitis in high-income countries and some developing regions. The vaccine was found to be highly effective in adolescents aged 11-17 years, with 99-100% protection after two or three doses.
A bivalent HPV vaccine has been shown to offer excellent protection against the most serious immediate precursor to invasive cervical cancer. The vaccine also partially protects against four other cancer-causing HPV types, which together with HPV16/18 cause about 85% of cervical cancer worldwide.
The new decade of vaccines brings hope for disease prevention through innovative technologies like glycoconjugate vaccines and reverse vaccinology. Despite challenges, vaccines have already led to significant reductions in morbidity and mortality due to diseases like smallpox, measles, and meningitis.
A new universal influenza vaccine candidate, VAX102, has safely produced an immune response in humans and could eliminate the need for annual flu vaccine updates. The vaccine targets a protein called M2e, found on the surface of the influenza A virus, which remains relatively unchanged over time.
Researchers discovered that HIV envelope protein complex can be exposed to raise more broadly cross-reactive antibodies against HIV. This finding could lead to the development of effective vaccines against HIV and AIDS.
A recent study found that targeted human papillomavirus (HPV) vaccination in men who have sex with men is a cost-effective intervention against anal cancer. The quadrivalent vaccine has demonstrated high efficacy against anal lesions and genital warts in young MSM. Vaccination at ages 12-26 years without previous exposure to HPV-target...
A new study reveals that resident dendritic cells capture and present flu viruses to B-lymphocytes, activating an immune response. Harnessing this function could lead to more effective vaccines.
Researchers discuss personalized treatment options for early-stage lung cancer, using targeted therapies and cancer vaccines. A gene signature is being used to predict which patients will benefit from an immune-boosting vaccine designed to target MAGE-A3 protein.
Scientists are working on a new strategy to prevent the spread of mosquito-borne diseases by disabling insects from transmitting viruses. The approach targets ticks, sand flies, and mosquitoes, which are responsible for most deaths worldwide.
The Medical College of Georgia has received a $100,000 grant from the Bill & Melinda Gates Foundation to develop an antibody-based vaccine against HIV-1. Dr. Pandelakis Koni aims to target conserved areas of the virus's sugar coating, which he believes could be vulnerable to attack.
A new vaccine targets glioblastoma multiforme, doubling survival time and more than quadrupling progression-free survival. The vaccine has caused virtually no side effects, making it a promising therapy for this deadly brain tumor.
A new vaccine targeting human cytomegalovirus (CMV) shows promise in delaying the recurrence of deadly brain tumors, glioblastoma multiforme (GBM). The study found that patients receiving the vaccine experienced a significant delay in tumor regrowth, with overall survival extended to over 20 months.
Researchers report a significant decline in invasive pneumococcal disease rates in all age groups post-PCV7 introduction. Disease caused by non-PCV7 serotypes, especially 19A, is emerging and accounts for nearly all IPD cases.
A new study suggests that a vaccine targeting Epstein-Barr virus may prevent infectious mononucleosis, commonly known as “mono” or “glandular fever.” The vaccine was found to reduce the proportion of symptomatic EBV infections from 10% in control groups to 2% in vaccinated individuals.
Scientists at Children's Hospital of Pittsburgh have identified a plasmid-deficient strain of Chlamydia that fails to cause disease in animal models. This finding represents a major step forward in developing a vaccine against chlamydial disease, with potential to protect against damage to reproductive organs and infertility.
A new HPV vaccine has shown near 100 percent efficacy in preventing the two types of human papillomavirus responsible for most cases of cervical cancer. The vaccine targets HPV types 16 and 18, causing about 70 percent of all cases of cervical cancer.
Since the introduction of PREVNAR, antibiotic-resistant invasive pneumococcal disease (IPD) has decreased by 87% among all ages, 98% among children under two, and 79% among adults over 65. The vaccine has also reduced IPD caused by penicillin-resistant strains targeted by the vaccine.
Researchers sequenced and analyzed over 1.8 million genetic codes to determine functions of genes involved in polysaccharide capsule production. The new vaccine protects children from many common serotypes, but monitoring is needed to track potential changes in capsular types.
Researchers at Rockefeller University have been selected to develop new vaccines targeting dendritic cells to stimulate stronger immune responses against various diseases. The project aims to create long-lasting protective immunity against HIV, malaria, and certain forms of cancer.
Rabies experts predict that raccoon rabies could spread rapidly across Ohio, with the virus potentially covering the state within 41 months. The study suggests that a strategic approach to controlling the spread of the disease is needed, including early detection and high-powered intervention programs.
Researchers developed a broad-based vaccination for Lyme disease by targeting white-footed mice, which play a key role in spreading the disease. The study found that vaccinating these mice reduced nymphal infection prevalence by 16% and had potential implications for preventing other vector-borne diseases.
Researchers have developed a vaccine that targets the anthrax capsule, providing improved protection against experimental infection. The study showed that mice vaccinated with the capsule vaccine survived challenge doses of spores, demonstrating the effectiveness of this new approach.